聚乙二醇干扰素联合核苷酸类似物治疗慢性乙型肝炎的临床

StephenW

Clinical characteristics of chronic hepatitis B cured by peginterferon in combination with nucleotide analogs

    Xuli Bao 1
    Jia Guo 1
    Fang Xiong
    Yao Gao
    Na Gu
    Jun Lu 1
    Show all authors
    Show footnotes

Open AccessPublished:May 28, 2020DOI:https://doi.org/10.1016/j.ijid.2020.05.041

Highlights

    •
    Individualized extension of combination therapy can achieve clinical cure for CHB.
    •
    Patients with low baseline HBVDNA and week 48 HBsAg achieve HBsAg clearance more quickly.
    •
    Consolidation therapy after HBsAg clearance and high HBsAb level can reduce recurrence.

Abstract
Objectives
The purpose of this study was to analyze the clinical characteristics of chronic hepatitis B (CHB) cured by antiviral therapy.
Methods
Forty-two patients with CHB were enrolled. All patients had been treated with peginterferon (Peg-IFN) in combination with nucleoside analogue (NA) therapy for variable amounts of time, and all had been successfully cured of the disease.
Results
The combined treatment time for all participants was 124.7 ± 58.8 weeks, and the average Peg-IFN treatment time was 102.6 ± 56.1 weeks. At 24 weeks, Hepatitis B surface antigen (HBsAg) and Hepatitis B e antigen (HBeAg) had decreased more than 50% from baseline. Multivariate logistic regression analysis of the week 96 HBsAg-clearing group and the non-HBsAg-clearing group showed a statistically significant difference in baseline HBV DNA levels and week 48 HBsAg levels. Those which baseline HBV DNA was < 2.75 log10 IU/mL, and week 48 HBsAg levels were < 0.88 log10 IU/mL were more likely to achieve rapid HBsAg clearance at 96 weeks. This suggests that low levels of baseline HBV DNA and week 48 HBsAg are a predictor of rapid HBsAg clearance at 96 weeks.
Conclusions
Individualized extension of combination therapy to more than 96 weeks depending on the patient’s response and adverse reaction conditions can help achieve a clinical cure. Patients with low baseline HBV DNA and low HBsAg levels at 48 weeks achieve HBsAg clearance more quickly than other populations.

StephenW

聚乙二醇干扰素联合核苷酸类似物治疗慢性乙型肝炎的临床特征

徐丽宝1
佳果1
方雄
高耀
那古
君路1号
显示所有作者
显示脚注

开放获取发布时间：2020年5月28日DOI：https：//doi.org/10.1016/j.ijid.2020.05.041

强调

•
个体化联合治疗扩展可以实现CHB的临床治愈。
•
基线HBVDNA低且第48周HBsAg的患者更快地达到HBsAg清除率。
•
清除HBsAg和高HBsAb水平后进行巩固治疗可以减少复发。

抽象
目标
这项研究的目的是分析通过抗病毒治疗治愈的慢性乙型肝炎（CHB）的临床特征。
方法
入选了42例CHB患者。所有患者均接受了聚乙二醇干扰素（Peg-IFN）联合核苷类似物（NA）治疗的时间不同，并且均已成功治愈。
结果
所有参与者的综合治疗时间为124.7±58.8周，平均Peg-IFN治疗时间为102.6±56.1周。在第24周时，乙肝表面抗原（HBsAg）和乙肝e抗原（HBeAg）与基线相比下降了50％以上。对96周HBsAg清除组和非HBsAg清除组的多因素logistic回归分析显示，基线HBV DNA水平和48周HBsAg水平具有统计学上的显着差异。那些基线HBV DNA <2.75 log10 IU / mL，而第48周HBsAg水平<0.88 log10 IU / mL的患者更有可能在96周时快速清除HBsAg。这表明基线HBV DNA水平低和第48周HBsAg可以预测96周时HBsAg快速清除。
结论
根据患者的反应和不良反应情况，将联合疗法个性化延长至96周以上可以帮助实现临床治愈。在第48周基线HBV DNA低且HBsAg水平低的患者比其他人群更快地实现HBsAg清除。

乙肝人1949

好的立意，但是这骚文章，完美的阐述了，啥是标准职称论文

StephenW

回复 乙肝人1949 的帖子

自己阅读:
https://www.ijidonline.com/article/S1201-9712(20)30348-9/pdf